https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-adap.y/adaptimmune-therapeutics
Research Adaptimmune Therapeutics' (OTCPK:ADAP.Y) fundamentals, past performance, valuation, dividends and more.
stock analysisadaptimmunetherapeuticssimplywall
https://www.adaptimmune.com/
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients
adaptimmune
https://fprimecapital.com/company/adaptimmune/
Nov 5, 2025 - Adaptimmune (NASDAQ: ADAP) is a cellular therapeutics company developing affinity enhanced T-cell receptor (TCR) engineered T-cells to treat solid tumor and...
adaptimmunefprimecapital
https://www.biospace.com/press-releases/adaptimmune-announces-changes-to-its-executive-leadership-team-based-in-the-uk
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood,...
executive leadership teamadaptimmuneannounceschangesbased